

[a]Patients in the selected regimen were further uptitrated to 9 mg/d if they had not reached 5.5 mg/dL serum phosphate level by Day 14 and if they had no TRAEs.

FIG. 1



(CR + PR)/N
ORR (95% CI)
Overall 40/99 40.4 (30.7 to 50.1)
Age
<65 years 14/38 36.8 (21.5 to 52.2)
≥65 years 26/61 42.6 (30.2 to 55)
<75 years 32/83 38.6 (28.1 to 49)
≥75 years 8/16 50.0 (25.5 to 74.5)
Sex
Male 30/76 39.5 (28.5 to 50.5)
Female 10/23 43.5 (23.2 to 63.7)
Race
White 31/74 41.9 (30.7 to 53.1)
Non-white 3/8 37.5 (4 to 71)
Region
USA 11/21 52.4 (31 to 73.7)
Non-USA 29/78 37.2 (26.5 to 47.9)
Baseline ECOG
0–1 39/92 42.4 (32.3 to 52.5)
2 1/7 14.3 (0 to 40.2)
Baseline hemoglobin level
<10 g/dl 8/15 53.3 (28.1 to 78.6)
≥10 g/dl 32/84 38.1 (27.7 to 48.5)
Baseline creatinine clearance
<60 ml/min 20/52 38.5 (25.2 to 51.7)
≥60 ml/min 20/47 42.6 (28.4 to 56.7)
Prior systemic therapy
None 4/11 36.4 (7.9 to 64.8)
1 line 17/45 37.8 (23.6 to 51.9)
≥2 lines 19/43 44.2 (29.3 to 59)
Any anti-PD(L)-1 13/22 59.1 (38.5 to 79.6)
0 20 40 60 80 100
ORR (%)

FIG. 2

FIG. 3A




FIG. 3B




FIG. 3C





FIG. 4


6 mg
Treatment ongoing
Treatment discontinuation
Responder (confirmed CR/PR)
Up-titrated subject
Complete response
Partial response
Stable disease
Progressive disease
0
5
10
15
20
Months



Median PFS = 5.5 months (95% CI, 4.2 to 6.0)
Progression/death events = 77
Progression-Free Survival (%)
100
80
60
40
20
0
8 mg
0 3 6 9 12 15 18
Months
No. at risk 99 63 35 16 6 1 0

FIG. 5A



Median OS = 13.8 months (95% CI, 9.8 to NE)
Survival events = 40
Overall Survival (%)
100
80
60
40
20
0
8 mg
0 3 6 9 12 15 18
Months
No. at risk 99 87 70 42 22 4 0

FIG. 5B



Median OS = 7.5 months (95% CI, 6.0 to 10.7)
10 mg
Overall Survival (%)
100
80
60
40
20
0
0 3 6 9 12 15 18 21 24 27
Months
No. at risk 33 30 22 13 10 8 8 6 2 0

FIG. 6A



Median OS = 8.6 months (95% CI, 6.5 to 9.7)
6 mg
Overall Survival (%)
100
80
60
40
20
0
0 3 6 9 12 15 18 21 24 27
Months
No. at risk 78 62 50 32 20 13 10 1 0 0

FIG. 6B